Page URL: https://www.bionews.org.uk/page_145661

Health reports from direct-to-consumer genetic tests 'woefully incomplete'

21 October 2019
Appeared in BioNews 1020

Direct-to-consumer (DTC) genetic tests should not be used as a basis for medical decision making, according to two separate studies released last week.

The UK study was headed by Anneke Lucassen, Professor of Clinical Genetics at the University of Southampton and published in the British Medical Journal.  

'Genetic tests sold online and in shops should absolutely not be used to inform health decisions without further scrutiny,' she told The Guardian. 'Finding a "health risk" via these tests often does not mean a person will go on to develop the health problem in question, while "reassuring" results might be unreliable.'

The US study presented by Dr Edward Esplin at American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, Texas, focused on three genes: MUTYH, associated with colorectal cancers, and BRCA1 and BRCA2, both associated with breast and ovarian cancers. Hundreds or thousands of variants in each of these genes can affect cancer risk, however, most DTC tests only look at a very small number of variants. 

FDA-approved DTC tests in the US cover only three BRCA variants, all of which are most common among people of Ashkenazi Jewish descent. Dr Esplin and his colleagues looked at the genomes of almost 120,000 patients who had been referred for clinical BRCA testing. Of the patients without Ashkenazi heritage, 94 percent had a mutation that would not have been detected, rising to 98 percent in those from Asian backgrounds and 99 percent in African-Americans.

Dr Esplin, who works for medical genetic testing company Invitae, refers to these missed variants as a 'clinical false-negative', adding that 'it could be the difference between preventing cancer and developing cancer.'

DTC company 23andme said that this is a 'false characterisation' as it makes clear that only certain variants are tested for, and that it does not claim to be a diagnostic test. 

Professor Lucassen's team estimate that a test for the three BRCA variants used by 23andme would miss around 80 percent of people in the UK with disease-causing BRCA variants.

Professor Lucassen explained her concern that receiving a negative result on a DTC test would likely be misinterpreted by some patients as an 'all clear':

'Most people who come to clinic ask: "Have I got the gene for breast cancer?" and imagine it's a single test, not that the test involves looking through around 20,000 letters of the genetic code to see if any one of them might be different.'

The BMJ paper also covers other aspects of DTC testing including polygenic risk scores, which are often misunderstood, not least by Health Secretary Matt Hancock earlier this year (see BioNews 992). His confusion illustrates the point these studies are making about how difficult it can be for non-specialists to correctly interpret genetic and genomic information, and to over- or underestimate their disease risk as a result. 

SOURCES & REFERENCES
Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing
STAT |  17 October 2019
Direct-to-consumer genetic testing
BMJ |  16 October 2019
Genetic testing kits 'may wrongly reassure those at risk of cancer'
The Guardian |  17 October 2019
Genetic tests: Experts urge caution over home testing
BBC News |  17 October 2019
Researchers quantify limitations of health reports from direct-to-consumer genetic tests
EurekAlert! |  17 October 2019
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
4 November 2019 - by Rikita Patel 
New genetic variants found in an African population provide insights into human health, according to a large genome study...
28 October 2019 - by Laura Riggall 
By 2022 the world's consumer genetic testing market is expected to quadruple to £200 million, according to The Guardian. But while the popularity of DIY genetic testing has undergone huge expansion in recent years, doctors and scientists have called for a crackdown on tests offered by consumer genetics companies such as 23andMe and AncestryDNA...
7 October 2019 - by Dr Loredana Guglielmi 
Multigene testing for all women diagnosed with breast cancer would save thousands of lives each year in the UK and USA, suggests new research...
16 September 2019 - by Dr Maria Botcharova 
Seventeen former employees of a genetic testing company, Orig3n, have accused it of not meeting scientific standards and returning inaccurate results...
9 September 2019 - by Eleanor Taylor 
The Progress Educational Trust (PET), which publishes BioNews, held a public event at Manchester's Science and Industry Museum to discuss genomics...
27 August 2019 - by Charlott Repschlager 
An influential health group in the USA has concluded that more women could benefit from wider gene screening for hereditary breast or ovarian cancer...
22 July 2019 - by Shaoni Bhattacharya 
Geneticists in the UK have been speaking out against direct-to-consumer DNA testing after concerns over false positive results...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.